Electroporation-mediated siRNA delivery into tumors

Methods in Molecular Biology

Volumn 1121, Issue , 2014, Pages 131-138

  Takei, Yoshifumi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer therapy; Electroporation; Prostate cancer; Short interfering RNA (siRNA); Vascular endothelial growth factor (VEGF)

Indexed keywords

SMALL INTERFERING RNA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; ELECTRODE; ELECTROPORATION; GENE TARGETING; GENETIC TRANSFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; ELECTROPORATION; GENETIC THERAPY; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84934439618     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-9632-8_11     Document Type: Article

References (15)

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotideRNAs mediate interference in cultured mammalian cells. Nature 411:494-498
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans . Nature 391:806-811
3. Carpenter AE, Sabatini DM (2004) Systematic genome-wide screens of gene function. Nat Rev Genet 5:11-22
4. Zheng L, Liu J, Batalov S et al (2004) An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci USA 101:135-140
5. Karagiannis TC, El-Osta A (2004) Mechanism of RNA interference, in vivo and potential clinical applications. Cancer Biol Ther 3: 1069-1074
6. Ryther RCC, Flynt AS, Phillips JA III, Patton JG (2005) siRNA therapeutics: big potential from small RNAs. Gene Ther 12:5-11
7. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T (2004) A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 64: 3365-3370
8. Folkman J (1971) Tumor angiogenesis: therapeutic implications. New Engl J Med 285: 1182-1186
9. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
10. Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y, Yuzawa Y, Matsuo S, Muramatsu T, Kadomatsu K (2008) In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery effi ciency. Mol Cancer Ther 7:211-221
11. Takei Y, Kadomatsu K, Goto T, Muramatsu T (2006) Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 107:864-873
12. Takei Y, Kadomatsu K, Matsuo S et al (2001) Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 61:8486-8491
13. Takei Y, Kadomatsu K, Itoh H et al (2002) 5′-,3′-inverted thymidine-modifi ed antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 277:23800-23806
14. Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T (2005) Morpholino antisense oligomer targeting human midkine: its application for cancer therapy. Int J Cancer 114:490-497
15. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y (2009) Systemic delivery of siRNA specifi c to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer 125:2978-2990